ReviewZeitschrift fur Rheumatologie2026
[Why C-reactive protein is (usually) not high in SLE].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High levels of C‑reactive protein (CRP) in systemic lupus erythematosus are not usually a sign of disease activity but more of a severe bacterial infection. Why this is the case, even though levels of interleukin‑6 (IL-6) the most important CRP stimulator, are high in active SLE, has long been an intriguing question. Newly published results now provide an answer: in combination with interferon-alpha (IFNα), IL‑6 causes the IL‑6 receptor to be shed, i.e. enzymatically cleaved from the cell membrane. The soluble receptors constitute an IL‑6 buffer that inhibit IL‑6 biological activity in plasma. As this prevents IL‑6 from stimulating liver cells, no CRP is induced there. When IL‑6 levels are extremely high in the context of infections (and rarely lupus serositis or arthritis), the buffering capacity is exceeded and the hepatocytes respond by producing CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.